MARKET

ONCT

ONCT

Oncternal Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.930
-0.310
-7.31%
Closed 17:12 09/20 EDT
OPEN
4.000
PREV CLOSE
4.240
HIGH
4.100
LOW
3.890
VOLUME
636.54K
TURNOVER
--
52 WEEK HIGH
10.56
52 WEEK LOW
1.490
MARKET CAP
194.08M
P/E (TTM)
-6.7537
1D
5D
1M
3M
1Y
5Y
BRIEF-Celularity Says Co And Oncternal Therapeutics Enter Into Research Collaboration To Evaluate Targeted Placental-Derived Cellular Therapies
reuters.com · 23h ago
Celularity and Oncternal Therapeutics Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular Therapies
FLORHAM PARK, N.J. and SAN DIEGO, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (“Celularity”) (Nasdaq: CELU), a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic therapies, and Oncternal Therapeutics, Inc. (“O...
GlobeNewswire · 23h ago
Oncternal Therapeutics to Participate in September Investor Conferences
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the following conferences in the month of September:
GlobeNewswire · 09/09 20:01
Return on Capital Employed Overview: Oncternal Therapeutics
Benzinga Pro data, Oncternal Therapeutics (NASDAQ:ONCT) reported Q2 sales of $883.00 thousand. Earnings fell to a loss of $7.69 million, resulting in a 29.05% decrease from last quarter.
Benzinga · 09/02 15:31
Oncternal Therapeutics (NASDAQ:ONCT) pulls back 13% this week, but still delivers shareholders respectable 33% return over 1 year
Some Oncternal Therapeutics, Inc. ( NASDAQ:ONCT ) shareholders are probably rather concerned to see the share price...
Simply Wall St. · 08/16 17:17
Analyzing Oncternal Therapeutics's Unusual Options Activity
On Friday, shares of Oncternal Therapeutics (NASDAQ:ONCT) saw unusual options activity. After the option alert, the stock price moved up to $4.21.
Benzinga · 08/06 16:19
Oncternal Therapeutics (ONCT) Reports Q2 Loss, Lags Revenue Estimates
Zacks.com · 08/05 21:25
Recap: Oncternal Therapeutics Q2 Earnings
Shares of Oncternal Therapeutics (NASDAQ:ONCT) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 52.94% over the past year to ($0.16), which missed the estimate of ($0.14).
Benzinga · 08/05 21:23
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ONCT. Analyze the recent business situations of Oncternal Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ONCT stock price target is 15.50 with a high estimate of 21.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 93
Institutional Holdings: 13.27M
% Owned: 26.87%
Shares Outstanding: 49.39M
TypeInstitutionsShares
Increased
24
5.44M
New
26
1.31M
Decreased
18
2.89M
Sold Out
10
542.35K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.58%
Pharmaceuticals & Medical Research
-1.08%
Key Executives
Non-Executive Chairman/Independent Director
David Hale
President/Chief Executive Officer/Director
James Breitmeyer
Chief Financial Officer/Treasurer/Secretary
Richard Vincent
Chief Scientific Officer
Gunnar Kaufmann
General Counsel
Chase Leavitt
Other
Salim Yazji
Director
Robert Wills
Director
Nakanishi Xin
Independent Director
Michael Carter
Independent Director
Daniel Kisner
Independent Director
William LaRue
Independent Director
Rosemary Mazanet
Independent Director
Charles Theuer
No Data
About ONCT
Oncternal Therapeutics, Inc., formerly GTX, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of product candidates for the treatment of cancers. Its pipeline includes cirmtuzumab, TK-216 and chimeric antigen receptor T-cell (CAR-T). Its cirmtuzumab product candidate is an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) monoclonal antibody. Cirmtuzumab is in a Phase-I/II clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). TK216 is a small-molecule compound designed to inhibit the biological activity of E26 transformation-specific (ETS) oncoproteins. TK216 is being evaluated in combination with vincristine in a Phase-I clinical trial in patients with relapsed or refractory Ewing sarcoma. Its CAR-T product candidate targets ROR-1 and is in preclinical development as a treatment for hematologic cancers and solid tumors.

Webull offers kinds of Oncternal Therapeutics Inc stock information, including NASDAQ:ONCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ONCT stock methods without spending real money on the virtual paper trading platform.